Study of Eribulin in Children With Cancer to Determine Safety

Summary

This is a study for children with cancer with no curative treatment options. The investigators will be giving eribulin, a new chemotherapy agent, for the first time to children. This study is designed to determine a safe dose the investigators can give to children in larger studies. The investigators will be monitoring the children on this study for the safety of the treatment and levels of eribulin in the blood after treatment. The investigators will also study the effect of the agent on the cancer.

Timeline

Start

2014-02-01

Primary completion

2018-06

Completion

2018-06

Drugs

Indications